04:32 PM EST, 12/08/2025 (MT Newswires) -- Assembly Biosciences ( ASMB ) said Monday interim Phase 1b results showed its weekly oral candidate ABI-1179 cut HSV-2 shedding by 98% and virologically confirmed genital lesion rates 91% versus placebo.

The company said its monthly oral ABI-5366 regimen reduced Herpes Simplex Virus-2 shedding by 76% and virologically confirmed lesion rates by 88%.

Both candidates were reported as well-tolerated with no serious adverse events.

Shares of the company were up 3.73% in after-hours trading.